ARS Pharmaceuticals’ Neffy Nasal Spray approved in Japan for Emergency Allergic Reaction Treatment
September 19, 2024 – ARS Pharmaceuticals (SPRY), a biopharmaceutical company focused on developing treatments for acute medical conditions, has announced that its nasal spray, Neffy, has received approval from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). This approval marks a significant milestone for the company,paving the way for the treatment to become available in Japan for the emergency treatment of allergic reactions.
what is Neffy?
Neffy is a pre-filled,preservative-free nasal spray formulation of epinephrine,indicated for the emergency treatment of anaphylaxis – a severe,perhaps life-threatening allergic reaction.The approved dosages in Japan are 1mg and 2mg, suitable for both adults and children weighing over 15 kg (approximately 33 pounds). Epinephrine is the first-line treatment for anaphylaxis, working by rapidly reversing the symptoms of a severe allergic reaction, such as airway constriction, swelling, and a sudden drop in blood pressure.
The Approval and Partnership with Alfresa Holdings
The PMDA approval follows an exclusive licensing agreement signed in 2020 between ARS Pharma and Alfresa Holdings (2784.T), a leading Japanese pharmaceutical company. This agreement granted Alfresa Holdings the exclusive rights to market and distribute neffy in Japan. According to a statement released by Alfresa, Neffy is anticipated to be available to Japanese patients in the fourth quarter of 2025.https://www.alfresa.co.jp/en/
Market Reaction and Company Performance
News of the Japanese approval caused a positive market reaction, with ARS Pharmaceuticals’ stock price increasing by 7.7% to $10.69 in pre-market trading. https://finance.yahoo.com/quote/SPRY/ However, despite this recent surge, the company’s stock has experienced a 5.88% decline since the beginning of the year.
Importance of the Japanese Market
The approval in Japan represents a considerable opportunity for ARS Pharmaceuticals. Japan has a growing need for accessible and convenient epinephrine delivery options for individuals at risk of anaphylaxis. The nasal spray formulation of Neffy offers an option to conventional epinephrine auto-injectors, potentially improving ease of use and patient compliance.
Looking Ahead
ARS Pharmaceuticals continues to focus on expanding the availability of Neffy to other global markets. The company is also working on further developing its pipeline of acute care treatments. The successful launch of Neffy in Japan will be a key indicator of the company’s ability to execute its commercial strategy and deliver value to patients and shareholders.
Primary Topic: ARS Pharmaceuticals’ Neffy nasal spray approval in Japan.
Primary Keyword: Neffy Japan approval
Secondary Keywords: epinephrine nasal spray, anaphylaxis treatment, ARS Pharmaceuticals, Alfresa Holdings, allergic reaction treatment, emergency allergy treatment, SPRY stock, PMDA approval.